|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / QuickGO|
Hyaluronidases are a family of enzymes that catalyse the degradation of hyaluronic acid (HA). Karl Meyer classified these enzymes in 1971 into three distinct groups, a scheme based on the enzyme reaction products. The three main types of hyaluronidases are two classes of eukaryotic endoglycosidase hydrolases and a prokaryotic lyase-type of glycosidase.
In humans, there are five functional hyaluronidases: HYAL1, HYAL2, HYAL3, HYAL4 and HYAL5 (also known as SPAM1 or PH-20); plus a pseudogene, HYAL6 (also known as HYALP1). The genes for HYAL1-3 are clustered in chromosome 3, while HYAL4-6 are clustered in chromosome 7. HYAL1 and HYAL2 are the major hyaluronidases in most tissues. GPI-anchored HYAL2 is responsible for cleaving high-molecular weight HA, which is mostly bound to the CD44 receptor. The resulting HA fragments of variable size are then further hydrolized by HYAL1 after being internalized into endo-lysosomes; this generates HA oligosaccharides.
According to their enzymatic mechanism, hyaluronidases are hyaluronoglucosidases (EC 18.104.22.168), i.e. they cleave the (1->4)-linkages between N-acetylglucosamine and glucuronate. The term hyaluronidase may also refer to hyaluronoglucuronidases (EC 22.214.171.124), which cleave (1->3)-linkages. In addition, bacterial hyaluronate lyases (EC 126.96.36.199) may also be referred to as hyaluronidases, although this is uncommon.
Use as a drug
|AHFS/Drugs.com||Consumer Drug Information|
|Chemical and physical data|
|Molar mass||53870.9 g/mol|
|(what is this?)|
By catalyzing the hydrolysis of hyaluronan, a constituent of the extracellular matrix (ECM), hyaluronidase lowers the viscosity of hyaluronan, thereby increasing tissue permeability. It is, therefore, used in medicine in conjunction with other drugs to speed their dispersion and delivery. Common applications are ophthalmic surgery, in combination with local anesthetics. It also increases the absorption rate of parenteral fluids given by hypodermoclysis, and is an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is also used for extravasation of hyperosmolar solutions.
Brand names of animal-derived hyaluronidase include Hydase (developed and manufactured by PrimaPharm Inc., distributed by Akorn Inc.), which has been FDA-approved as a "thimerosal-free" animal-derived hyaluronidase, Vitrase (Bausch + Lomb/Valeant Pharmaceuticals), Amphadase (Amphastar Pharmaceuticals), and Wydase. Wydase, however, is no longer manufactured.
On December 2, 2005, the FDA approved a synthetic (recombinant or rDNA) "human" hyaluronidase, Hylenex (Halozyme Therapeutics). The FDA also approved HyQvia in late 2014, a form of sub-cutaneous immunoglobulin (SCIG) that uses Hylenex to allow for a far greater volume of SCIG to be administered than would normally be possible to administer sub-cutaneously, providing a form of SCIG that can be dosed on a monthly basis, a longer period of time than other forms of SCIG allow. HyQvia had a rate of systemic adverse effects higher than traditional subcutaneous forms of immunoglobulin injection, but lower than those typical in IVIG patients.
Role in cancer
The role of hyaluronidases in cancer has been historically controversial due to contradictory observations, namely that levels of hyaluronidase (HYAL1/2) are increased in some cancers (colorectal, bladder, prostate, breast and brain), whereas low expression of HYAL1 is correlated with a decrease in survival of pancreatic adenocarcinoma patients. The reason for this apparent contradiction is that both the accumulation of HA (due to increased HAS levels and decreased HYAL levels), and the degradation of HA into HA oligosaccharides by high HYAL levels result in increased tumor malignancy.
Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. Limited data support a role of lysosomal hyaluronidases in metastasis, while other data support a role in tumor suppression. Other studies suggest no contribution or effects independent of enzyme activity. Non-specific inhibitors (apigenin, sulfated glycosaminoglycans) or crude enzyme extracts have been used to test most hypotheses, making data difficult to interpret. It has been hypothesized that, by helping degrade the ECM surrounding the tumor, hyaluronidases help cancer cells escape from primary tumor masses. However, studies show that removal of hyaluronan from tumors prevents tumor invasion. Hyaluronidases are also thought to play a role in the process of angiogenesis, although most hyaluronidase preparations are contaminated with large amounts of angiogenic growth factors.
Role in pathogenesis
Some bacteria, such as Staphylococcus aureus, Streptococcus pyogenes, and Clostridium perfringens, produce hyaluronidase as a means of using hyaluronan as a carbon source. It is often speculated that Streptococcus and Staphylococcus pathogens use hyaluronidase as a virulence factor to destroy the polysaccharide that holds animal cells together, making it easier for the pathogen to spread through the tissues of the host organism, but no valid experimental data are available to support this hypothesis.
Role in fertilization
In most mammalian fertilization, hyaluronidase is released by the acrosome of the sperm cell after it has reached the oocyte, by digesting hyaluronan in the corona radiata, thus enabling conception. Gene-targeting studies show that hyaluronidases such as PH20 are not essential for fertilization, although exogenous hyaluronidases can disrupt the cumulus matrix.
The majority of mammalian ova are covered in a layer of granulosa cells intertwined in an ECM that contains a high concentration of hyaluronan. When a capacitated sperm reaches the ovum, it is able to penetrate this layer with the assistance of hyaluronidase enzymes present on the surface of the sperm. Once this occurs, the sperm is capable of binding with the zona pellucida, and the acrosome reaction can occur.
- Meyer, K (1971). "Hyaluronidases". In Boyer PD. Enzymes. V. New York: Academic Press. pp. 307–320. ISBN 978-0-12-122705-0.
- Stern, Robert; Kogan, Grigorij; Jedrzejas, Mark J.; Šoltés, Ladislav (November 2007). "The many ways to cleave hyaluronan". Biotechnology Advances. 25 (6): 537–557. doi:10.1016/j.biotechadv.2007.07.001.
- Csóka, Antonei Benjamin; Scherer, Stephen W.; Stern, Robert (September 1999). "Expression Analysis of Six Paralogous Human Hyaluronidase Genes Clustered on Chromosomes 3p21 and 7q31". Genomics. 60 (3): 356–361. PMID 10493834. doi:10.1006/geno.1999.5876.
- Csoka AB, Frost GI, Stern R (December 2001). "The six hyaluronidase-like genes in the human and mouse genomes". Matrix biology : journal of the International Society for Matrix Biology. 20 (8): 499–508. PMID 11731267. doi:10.1016/S0945-053X(01)00172-X.
- Chanmee, Theerawut; Ontong, Pawared; Itano, Naoki (May 2016). "Hyaluronan: A modulator of the tumor microenvironment". Cancer Letters. 375 (1): 20–30. PMID 26921785. doi:10.1016/j.canlet.2016.02.031.
- "Hyaluronidase". ENZYME. ExPASy. Retrieved 17 November 2016.
- "Halozyme Therapeutics and Baxter Healthcare Corporation Announce FDA Approval of Hylenex". Archived from the original on October 18, 2007. Retrieved 2008-11-07.
- "September 12, 2004 Approval Letter". FDA. FDA.gov. Retrieved 20 November 2015.
- Sanford, Mark (13 June 2014). "Human Immunoglobulin 10% with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders". BioDrugs. 28 (4): 411–420. doi:10.1007/s40259-014-0104-3.
- "Chemotherapy extravasation guideline" (PDF). WOSCAN Cancer Nursing and Pharmacy Group. September 2009. Retrieved 4 June 2017.
- Bouga, Helen; Tsouros, Isidoros; Bounias, Dimitrios; Kyriakopoulou, Dora; Stavropoulos, Michael S; Papageorgakopoulou, Nikoletta; Theocharis, Dimitrios A; Vynios, Demitrios H (17 September 2010). "Involvement of hyaluronidases in colorectal cancer". BMC Cancer. 10 (1). doi:10.1186/1471-2407-10-499.
- Cheng, XB; Sato, N; Kohi, S; Yamaguchi, K (2013). "Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma.". PloS one. 8 (11): e80765. PMID 24244714.
- Hautmann, SH; Lokeshwar, VB; Schroeder, GL; Civantos, F; Duncan, RC; Gnann, R; Friedrich, MG; Soloway, MS (June 2001). "Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer.". The Journal of Urology. 165 (6 Pt 1): 2068–74. PMID 11371930.
- Rahmanian, Mehdi; Heldin, Paraskevi (10 February 2002). "Testicular hyaluronidase induces tubular structures of endothelial cells grown in three-dimensional colagen gel through a CD44-mediated mechanism". International Journal of Cancer. 97 (5): 601–607. doi:10.1002/ijc.10087.
- Starr CR, Engleberg NC (January 2006). "Role of hyaluronidase in subcutaneous spread and growth of group A streptococcus". Infection and immunity. 74 (1): 40–8. PMC . PMID 16368955. doi:10.1128/IAI.74.1.40-48.2006.
- Zukaite V, Biziulevicius GA (March 2000). "Acceleration of hyaluronidase production in the course of batch cultivation of Clostridium perfringens can be achieved with bacteriolytic enzymes". Letters in applied microbiology. 30 (3): 203–6. PMID 10747251. doi:10.1046/j.1472-765x.2000.00693.x.
- Isoyama, T. (13 July 2005). "Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases". Glycobiology. 16 (1): 11–21. PMID 16166602. doi:10.1093/glycob/cwj036.
- Alberts, Bruce (2008). Molecular biology of the cell. New York: Garland Science. p. 1298. ISBN 0-8153-4105-9.